« Back
Home /
Clozapine N-oxide

Clozapine N-oxide

Item no.	HY-17366-1mg
Manufacturer	MedChem Express
CASRN	34233-69-7
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Brain Cancer Nervous System Cancer
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Wess J, et al. Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci. 2013 Jul;34(7):385-92.\|[2]Silva RR, et al. Evaluation of Functional Selectivity of NSC 170973, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Front Pharmacol. 2019 Jun 4;10:628.\|[3]Zorn SH, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994 Nov 15;269(3):R1-2.\|[4]Manvich DF, et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep. 2018 Mar 1;8(1):3840.\|[5]van der Peet PL, et al. Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs. MethodsX. 2018 Mar 23;5:257-267.\|[6]Joseph Cichon, et al. Branch-specific dendritic Ca(2+) spikes cause persistent synaptic plasticity. Nature. 2015 Apr 9;520(7546):180-5.\|[7]Rodd ZA, et al. CNO Administration Increases Dopamine and Glutamate in the Medial Prefrontal Cortex of Wistar Rats: Further Concerns for the Validity of the CNO-activated DREADD Procedure. Neuroscience. 2022 May 21;491:176-184. Acta Pharm Sin B. 2024 Aug 10.\|Acta Pharmacol Sin. 2023 Jan 25.\|Acta Pharmacol Sin. 2024 Dec 11.\|Acta Physiol. 2023 Jan 4;e13917.\|Adv Sci (Weinh). 2023 Apr 14;e2204824.\|Adv Sci (Weinh). 2023 Jun 16;e2301110.\|Adv Sci (Weinh). 2024 Aug 9:e2400253.\|Adv Sci (Weinh). 2024 Dec 11:e2410728.\|Adv Sci (Weinh). 2025 Feb 17:e2414723.\|Adv Sci (Weinh). 2025 Mar 16:e2412822.\|Anesthesiology. 2021 Jul 13.\|Anesthesiology. 2021 Jul 16.\|Biol Psychiatry. 2017 May 1;81(9):737-747.\|bioRxiv. 2023 Oct 9.\|bioRxiv. 2024 Apr 29.\|bioRxiv. 2024 July 23.\|Brain Behav Immun. 2023 Jun 5;S0889-1591(23)00141-1.\|Brain Commun. 30 August 2022.\|Brain Stimul. 2023 Dec 23;17(1):49-64.\|Cell Metab. 2022 Feb 1;34(2):285-298.e7.\|Cell Rep. 2021 Mar 23;34(12):108889.\|Cell Rep. 2023 Dec 3;42(12):113551.\|Cell Rep. 2023 Mar 21;42(4):112290.\|Cell Rep. 2024 Dec 10;43(12):115074.\|Cell Rep. 2024 Feb 17;43(2):113804.\|Cell Rep. 2024 Nov 19;43(12):114983.\|Cell Rep. 2024 Oct 3;43(10):114800.\|CNS Neurosci Ther. 2022 Nov 15.\|CNS Neurosci Ther. 2023 Dec 17.\|CNS Neurosci Ther. 2024 Jun;30(6):e14782.\|CNS Neurosci Ther. 2024 Mar;30(3):e14675.\|Commun Biol. 2021 Sep 16;4(1):1088.\|Commun Biol. 2023 Jan 14;6(1):50.\|Ecotoxicol Environ Saf. 2023 Jun 29;262:115205.\|Ecotoxicol Environ Saf. 2024 Nov 30:289:117392.\|Elife. 2021 Sep 16;10:e67535.\|Elife. 2024 May 29.\|Elife. 2024 Nov 20:13:RP97954.\|Exp Neurol. 2025 Feb 26:387:115193.\|FASEB J. 2020 Sep;34(9):11913-11924.\|Front Cell Neurosci. 2021 Apr 30;15:671473.\|Front Neurosci. 2020 Jul 14;14:646.\|iScience. 2023 Aug 14.\|iScience. 2023 Oct 20.\|iScience. 2024 Oct 24;27(11):111251.\|J Affect Disord. 2024 Dec 3:S0165-0327(24)01996-7.\|J Neuroinflammation. 2022 Jun 27;19(1):166.\|J Neuroinflammation. 2022 May 27;19(1):123.\|J Neuropathol Exp Neurol. 2023 Jul 21;nlad056.\|J Neurosci. 2021 Oct 11;JN-RM-0881-21.\|J Neurosci. 2024 Jul 17:e0740242024.\|J Neurosci. 2024 May 14:e0222242024.\|J Psychiatry Neurosci. 2024 May 30;49(3):E192-E207.\|Life Metab. 2023 Feb 4.\|Life Sci. 2020 Oct 1;258:118099.\|Mol Neurobiol. 2024 Aug 23.\|Nat Commun. 2020 Jun 5;11(1):2847. \|Nat Commun. 2020 Nov 27;11(1):6045.\|Nat Commun. 2022 Apr 25;13(1):2233.\|Nat Commun. 2023 Apr 17;14(1):2182.\|Nat Commun. 2024 Oct 5;15(1):8632.\|Nat Neurosci. 2022 Nov 17.\|Nat Neurosci. 2023 Apr;26(4):542-554.\|Neural Regen Res. 2024 Feb;19(2):425-433.\|Neurobiol Dis. 2023 May 12;106155.\|Neurobiol Stress. 22 September 2022, 100492.\|Neuron. 2024 Apr 16:S0896-6273(24)00235-6.\|Neuropharmacology. 2018 Jun;135:474-486.\|Neuropharmacology. 2025 Apr 1:267:110301.\|Neuropsychopharmacology. 2022 Dec 16.\|Neuropsychopharmacology. 2024 Jan 5.\|Neurosci Bull. 2021 Jun 18.\|Neurosci Bull. 2021 May;37(5):597-610.\|Neurosci Bull. 2022 Nov 7.\|Neurosci Bull. 2023 Jan 11.\|Neuroscience. 2019 Aug 21;414:299-310. \|P Natl Acad Sci USA. 13, 2021 118 (28) e2103505118.\|Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16583-16592.\|Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2215590120.\|Prog Neuropsychopharmacol Biol Psychiatry. 18 December 2021, 110496.\|Psychoneuroendocrinology. 2020 Jul;117:104690.\|Psychopharmacology (Berl). 2024 May 14.\|Res Sq. 2024 Jul 10.\|Research Square Preprint. 2021 Mar.\|Research Square Preprint. 2023 Sep 22.\|Research Square Print. September 6th, 2022\|SSRN. 2023 Jul 18.\|SSRN. 2024 Oct 30.\|Theranostics. 2023 May 11;13(9):2946-2961.\|Theranostics. 2024 Jan 1;14(2):480-495.\|Transl Psychiatry. 2020 Jun 20;10(1):202.\|University of Michigan, Horace H. Rackham School of Graduate Studies. 2018 Oct.\|Cells. 2022 Dec 21;12(1):26.\|Cells. 2023, 12(1), 26.\|Exp Neurol. 2024 Apr 27:114801.\|Fundam Res. 2024 Mar 19.\|iScience. 2022: 105840.\|Pharmacol Res. 2023 Apr 15;106773.
Smiles	[O-][N+]1(C)CCN(C2=NC3=CC(Cl)=CC=C3NC4=CC=CC=C42)CC1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Dopamine Receptor; Drug Metabolite; mAChR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	342.82
Product Description	Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide can't cross the blood-brain barrier[1][2][3][4]. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist[5][6].
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Isoform	mAChR3; mAChR4
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-17366-1mg-safety-datasheet.pdf